SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing...
Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared t...
Keenova Therapeutics plc announced positive results from its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum) for the ...
Vaxart, Inc. announced topline data from the approximately 400-participant sentinel safety cohort of its Phase 2b clinical trial evaluating the Company&r...
TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced to...
Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with...
SK bioscience was selected to lead the Gates Foundation-funded ROTOR project, establishing a global collaboration framework. SK bioscience, PATH, Slal...
The University of California, Irvine (UC Irvine) School of Medicine and GlyTR Therapeutics have developed a next‑generation AAV‑mediated CAR T‑cell...
Following encouraging earlier-phase clinical data, the Company is advancing its acne trial ahead of schedule while maintaining atopic dermatitis global P...
End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming imm...
Phase I results provide platform-level validation supporting AdJane's broader development programs in pandemic preparedness, respiratory infectious disea...
- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thal...
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Diva...
© 2026 Biopharma Boardroom. All Rights Reserved.
